From The Motley Fool · Motley Fool Transcribing · · 2m
Cytosorbents Q3 2026 Earnings Breakthrough
Cytosorbents achieves first positive operating cash flow in Q3 2026 with 75% gross margins and German market rebound plans.
In brief
Cytosorbents achieves first positive operating cash flow in Q3 2026 with 75% gross margins and German market rebound plans. Cytosorbents reported $9.7 million Q3 revenue with 75% gross margins, achieved first positive operating cash flow, and plans to rebuild German sales team by early 2027. Originally reported by The…
Q3 Revenue Milestone
Cytosorbents reported $9.7 million Q3 revenue, a 3% year-over-year increase driven by distributor and strategic partner sales.
Gross Margin Improvement
Product gross margin reached 75%, up 200 basis points from prior quarter due to manufacturing efficiencies and optimized material sourcing.
Operating Expenses Down
Operating expenses declined 11% year over year to $8.5 million, reflecting headcount reductions and tighter cost controls.
Adjusted EBITDA Loss Improvement
Adjusted EBITDA loss narrowed 86% to $0.3 million, driven by higher gross profit and leaner cost structure.
Operating Cash Flow Breakthrough
Achieved first positive operating cash flow of $43,000 excluding restructuring payments, a key financial milestone.
German Market Strategy
Hired Alex Tiefenbacher as Senior VP of Direct Sales to rebuild German market and strengthen international channels.
German Revenue Decline
German revenue declined 20% to 21% year over year due to reduced sales force and territory coverage.
DrugSorb-ATR Clinical Evidence
BARC-4 bleeding reduction of 37% in 587 patients, representing statistically significant improvement in cardiac surgery.
De Novo Submission Prep
Preparing expanded evidence package for 250 patients to strengthen benefit-risk analysis for FDA De Novo submission.
HemoDefend-BGA Funding
Received $16 million in non-dilutive U.S. government funding for universal blood filtration technology.
Addressable Market Potential
Estimated $300 million to $2 billion addressable market for DrugSorb-ATR in U.S. and Canada.
Nasdaq Listing Requirement
Working to satisfy remaining Nasdaq continued listing requirement and debt restructuring by end of 2026.
Cash Position
Ended Q3 with $5.7 million cash and restricted cash, representing improved liquidity position.
Inventory Reduction
Inventory reduced from $5.3 million at end of 2025 to $3.2 million by end of Q3 2026.
Headcount Reduction
Reduced headcount by 24% since September 2025 through commercial restructuring and lean strategy.
Next Steps
Targeting early 2027 De Novo submission for DrugSorb-ATR with expanded clinical evidence package.
What it means
Cytosorbents reported $9.7 million Q3 revenue with 75% gross margins, achieved first positive operating cash flow, and plans to rebuild German sales team by early 2027.
